Breakthrough Therapies: Market Dynamics and Investment Opportunities

Breakthrough Therapies: Market Dynamics and Investment Opportunities

  • BCC Research
  • January 2017
  • Pharmaceutical
  • 250 pages

Report Description

1
1

The global market for breakthrough therapy designation (BTD) drugs should reach $99.2 billion by 2022 from $48.8 billion in 2017 at a compound annual growth rate (CAGR) of 15.2%, from 2017 to 2022.
The cancer therapy segment of the breakthrough therapy designation drugs industry is the largest market. The market is expected to grow from $19.6 billion in 2017 to $58.6 billion in 2022 at a CAGR of 24.5% for the period 2017-2022.
The CNS and neurology therapy segment of the breakthrough therapy designation drugs industry is expected to grow from $956 million in 2017 to $8.4 billion in 2022 at a CAGR of 54.3% for the period 2017-2022.

##img_0##

Have query on this report?

Make an Enquiry
Chapter 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE REPORT
SCOPE OF REPORT
INTENDED AUDIENCE
Summary Table : GLOBAL MARKET FOR BREAKTHROUGH THERAPY DESIGNATION DRUGS, BY THERAPY, THROUGH 2022
Table 1 : CDER BREAKTHROUGH THERAPY DESIGNATION REQUESTS RECEIVED BY FISCAL YEAR COHORT: JULY 9, 2012*-SEPTEMBER 30, 2015
Table 2 : CBER BREAKTHROUGH THERAPY REQUESTS FOR FINAL YEAR, OCTOBER 1, 2014SEPTEMBER 30, 2015
Table 3 : DRUGS GRANTED PRIME DESIGNATIONS, MARCH 7, 2016-AUGUST 24, 2016
Table 4 : GLOBAL MARKET FOR CV BREAKTHROUGH THERAPY DESIGNATION DRUGS, THROUGH 2022
Table 5 : FDA APPROVED CV BREAKTHROUGH THERAPY DESIGNATION DRUGS

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074